371244-06-3Relevant articles and documents
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs
Lodola, Alessio,Bertolini, Serena,Biagetti, Matteo,Capacchi, Silvia,Facchinetti, Fabrizio,Gallo, Paola Maria,Pappani, Alice,Mor, Marco,Pala, Daniele,Rivara, Silvia,Visentini, Filippo,Corsi, Mauro,Capelli, Anna Maria
, p. 4304 - 4315 (2017)
IC87114 [compound 1, (2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one)] is a potent PI3K inhibitor selective for the δ isoform. As predicted by molecular modeling calculations, rotation around the bond connecting the quinazolin-
METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS
-
, (2011/11/12)
The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in a
Inhibitors of human phosphatidylinositol 3-kinase delta
-
Page column 65-66, (2008/06/13)
Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.